Use access key #2 to skip to page content.
$36.97 0.37 (1.01%)
7/8/2008 4:00 PM

Merck & Co., Inc. (MRK)

CAPS Rating:
****

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.

View All Commentary (MRK)

Recs

10

Avatar biotechmgr (98.31) Submitted: 3/15/08 3:19 PM : Outperform Start Price: $43.50 MRK Score: -10.63

Merck is well positioned to become the industry leader over the next 5 years. The product pipeline has swelled under the leadership of Dr. Peter Kim. Innovations in vaccines are focusing on prevention not just cures. Cost savings efforts as well as focus on speed are continuous. Merck wants to be the winner again among big pharma. Merck is a highly ethical company and is working to remove any past taint from individual actions. Employee morale is increasing and the pride is returning in the post-Vioxx era under the leadership of Richard Clark. Key acquisitions such as siRNA (ex-Sirna Therapeutics) may provide the platform for current non-druggable targets.


Disclosure: I do work for Merck.

Report this Post Replies: 2 | Reply

Avatar sarkasm (96.50) Submitted: 6/03/08 2:24 PM

Recs: 0 | Rec This

I share your bullish view. What are "non-druggable targets"? Never heard this term.

Report this Post Reply

Avatar racer675 (< 20) Submitted: 6/12/08 8:59 PM

Recs: 0 | Rec This

RNA inhibition attempts to alter the expression of genes rather than biochemical pathways. Check out ISIS

Report this Post Reply

Featured Broker Partners